Does cannabis extract obtained from cannabis flowers with maximum allowed residual level of aflatoxins and ochratoxin A have an impact on human safety and health?

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
ABT-202
Identifiers
  • (R)-1-(Pyridin-3-yl)pyrrolidin-3-amine
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC9H13N3
Molar mass163.224 g·mol−1
3D model (JSmol)
  • N[C@@H]1CCN(C2=CC=CN=C2)C1
  • InChI=1S/C9H13N3/c10-8-3-5-12(7-8)9-2-1-4-11-6-9/h1-2,4,6,8H,3,5,7,10H2/t8-/m1/s1 ☒N
  • Key:LVGMMVAWLISWJD-MRVPVSSYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

ABT-202 is a drug developed by Abbott, which acts as an agonist at neural nicotinic acetylcholine receptors and has been researched for use as an analgesic, although it has not passed clinical trials.[1][2][3]

References

  1. ^ Jain KK (January 2004). "Modulators of nicotinic acetylcholine receptors as analgesics". Current Opinion in Investigational Drugs. 5 (1): 76–81. PMID 14983978.
  2. ^ Romanelli MN, Gratteri P, Guandalini L, Martini E, Bonaccini C, Gualtieri F (June 2007). "Central nicotinic receptors: structure, function, ligands, and therapeutic potential". ChemMedChem. 2 (6): 746–67. doi:10.1002/cmdc.200600207. PMID 17295372. S2CID 34763474.
  3. ^ Xu N, Kim GE, Gregg H, Wagdy A, Swaine BA, Chang MS, El-Shourbagy TA (September 2004). "Automated 96-well liquid-liquid back extraction liquid chromatography-tandem mass spectrometry method for the determination of ABT-202 in human plasma". Journal of Pharmaceutical and Biomedical Analysis. 36 (1): 189–95. doi:10.1016/j.jpba.2004.05.013. PMID 15351065.